Publications by authors named "Hans Skvara"

Claim this Profile
E
Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004-2022.
Thomas Graier, Wolfgang Salmhofer, Constanze Jonak, Wolfgang Weger, Claudia Zikeli, Hans Skvara

J Dtsch Dermatol Ges· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Entwicklung der Patientencharakteristika und der Wirksamkeit der Biologika-Therapie bei Patienten des Österreichischen Psoriasis-Registers von 2004 bis 2022].
Thomas Graier, Wolfgang Salmhofer, Constanze Jonak, Wolfgang Weger, Claudia Zikeli, Hans Skvara

J Dtsch Dermatol Ges· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IgE Depletion with Ligelizumab Does Not Significantly Improve Clinical Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis.
Christine Bangert, Christian Loesche, Hans Skvara, Regina Fölster-Holst, Jean-Philippe Lacour

J Invest Dermatol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic DMARDS (disease modifying antirheumatic drugs)].
Eva Rath, Michael Bonelli, Christina Duftner, Johann Gruber, Peter Mandl, Hans Skvara

Z Rheumatol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs).
Eva Rath, Michael Bonelli, Christina Duftner, Johann Gruber, Peter Mandl, Hans Skvara

Wien Klin Wochenschr· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis.
Thomas Graier, Wolfgang Weger, Paul-Gunther Sator, Wolfgang Salmhofer, Barbara Gruber, Hans Skvara

JAAD Int· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melanoma epidemiology of Austria reveals gender-related differences.
Nikolaus Duschek, Hans Skvara, Harald Kittler, Golnaz Delir, Astrid Fink

Eur J Dermatol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of skin lesions with a 3D stereovision camera system: validation and clinical applications.
Hans Skvara, Patrick Burnett, Julie Jones, Nikolaus Duschek, Peter Plassmann

Skin Res Technol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intradermal indocyanine green for in vivo fluorescence laser scanning microscopy of human skin: a pilot study.
Constanze Jonak, Hans Skvara, Rainer Kunstfeld, Franz Trautinger, Johannes A Schmid

PLoS One· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining in vivo reflectance with fluorescence confocal microscopy provides additive information on skin morphology.
Hans Skvara, Ulrike Plut, Johannes A Schmid, Constanze Jonak

Dermatol Pract Concept· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo fluorescence confocal microscopy: indocyanine green enhances the contrast of epidermal and dermal structures.
Hans Skvara, Harald Kittler, Johannes A Schmid, Ulrike Plut, Constanze Jonak

J Biomed Opt· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor.
Hans Skvara, Frank Kalthoff, Josef G Meingassner, Barbara Wolff-Winiski, Heinrich Aschauer

J Invest Dermatol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucocorticosteroids modify Langerhans cells to produce TGF-β and expand regulatory T cells.
Georg Stary, Irene Klein, Wolfgang Bauer, Frieder Koszik, Bärbel Reininger, Hans Skvara

J Immunol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De novo tuberculosis during infliximab therapy in a patient with Behçet disease.
Hans Skvara, Nikolaus Duschek, Franz Karlhofer

J Dtsch Dermatol Ges· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PKC inhibitor AEB071 may be a therapeutic option for psoriasis.
Hans Skvara, Markus Dawid, Elise Kleyn, Barbara Wolff, Josef G Meingassner

J Clin Invest· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mcl-1 blocks radiation-induced apoptosis and inhibits clonogenic cell death.
Hans Skvara, Christiane Thallinger, Volker Wacheck, Brett P Monia, Hubert Pehamberger

Anticancer Res· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Karl J Aichberger, Matthias Mayerhofer, Maria-Theresa Krauth, Hans Skvara, Stefan Florian

Blood· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limitations of dermoscopy in the recognition of melanoma.
Hans Skvara, Ligia Teban, Manfred Fiebiger, Michael Binder, Harald Kittler

Arch Dermatol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
Christiane Thallinger, Markus F Wolschek, Helmut Maierhofer, Hans Skvara, Hubert Pehamberger

Clin Cancer Res· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis